Drugs / isophane human insulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT01720303 | Sep 2002 → Apr 2003 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01865279 Comparator | Dec 2005 → Apr 2006 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 4 | NCT01467141 Background | Jun 2002 → Oct 2003 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| — | NCT00410033 Background | Dec 1989 → May 2006 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | isophane human insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01720303 ↗ |
| Modality | Protein / enzyme biologic | “Neutral Protein Hagedorn (NPH) insulin” PMID 17850471 ↗ Oct 2007 |
| Route | Subcutaneous | “May be administered s.c. (under the skin) in both treatment groups thrice daily” NCT01467141 ↗ |